The cover image may be different.

Translational Research in Stroke

Hardcover - 04 January 2018
Lapchak, Paul A. (Editor)
Yang, Guo-Yuan (Editor)
Rp 5,964,000
No Hidden Cost

Or   11928 PEC Points
Limited Stock
  
OTHER SERIES

New Free Shipping.
* Terms and Conditions
Quantity:
Delivered in 20 - 40 business days
BUY NOW

Description

This book mainly discusses the current status of stroke transnational research and allows the reader to understand the interplay of common comorbidities in the stroke population such as diabetes and hypertension, and provides insight into stroke targets to promote cell survival, angiogenesis, neurogenesis, and most importantly, functional recovery after stroke.
Throughout the world, stroke is still a leading cause of mortality and morbidity; each year approximately 15 million people worldwide suffer from stroke. Stroke is now the leading cause of death and disability in China. Large communities of stroke survivors are eagerly awaiting scientific advances in transnational stroke research that would offer neuroprotective therapeutics for acute stroke management, or rehabilitation and regenerative strategies utilizing novel stem cell-based approaches. While research is ongoing, the Editors have compiled this volume to help the further understanding of the pathophysiology of stroke and to review and identify future potential biomarkers. The book is written for students, researchers and physicians in neurosciences, neurology and neuroradiology.


Product Details

ISBN-10: 9811058032

ISBN-13: 9789811058035

Publisher: Springer       

Language: English

Age Range: NA - NA years

Grade Level: NA - NA

Hardcover: 581 Pages

Product Dimension (L x W x H): 24.05 x 16.15 x 3.66 CM

Shipping Weight: 1.10 Kg

Customer Reviews

Share your thoughts with other customers:
Write a Customer Review

There are no reviews for this product.

CONVENIENCE

BEST PRICE

SAFE/SECURITY

SERVICE

Customers who bought this also bought
 

 

DELIVERY BY:
PAYMENT METHODS:
 
SECURED BY:
View Mobile / Standard © 2011-2020 Periplus Holdings Ltd.